Denosumab meets prostate cancer endpoint

Amgen Inc. (NASDAQ:AMGN) said subcutaneous Xgeva denosumab met the primary endpoint of significantly improving the median time to first occurrence of bone metastasis or death from any cause vs. placebo in the Phase III 20050147 trial to prevent bone metastasis in men with castrate-resistant prostate cancer (p=0.03). Xgeva also met the secondary endpoint of significantly improving time to first occurrence of bone metastasis excluding death, but missed the secondary endpoint of significantly improving overall survival vs. placebo. The double-blind, international trial enrolled 1,432 men with CRPC. ...